The rhodopsin-like G protein-coupled receptor (GPCR) family includes the gonadotropin-releasing hormone receptor (GNRHR), which is made up of seven transmembrane helical domains connected by extracellular and intracellular segments. Gonadotrophs, pituitary cells that produce the gonadotrophins LH and FSH, have a GnRH receptor on their plasma membrane.
Different ligand preferences for GnRH-I and GnRH-II are shown by mammalian type I and type II GnRH receptors, respectively. All GnRH receptors activate the Gq/11 family of G proteins, which in turn activates the production of second messengers that in turn activates protein kinase C (PKC) through the phospholipase C pathway. LH and FSH are produced and released more quickly when the GnRH receptor is activated by GnRH analogues. GnRH receptors have a variety of medical and veterinary applications, including the study of breast and prostate cancer, the control of fertility, endometriosis, and other conditions.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V13956 | Degarelix acetate | 934246-14-7 | Degarelix acetate hydrate is a competitive, reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. |
|
V2801 | ELAGOLIX | 834153-87-6 | Elagolix (formerly NBI56418; ABT620; NBI-56418; ABT-620; trade name: Orilissa) is a potent, specific, orally bioavailable, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) used for pain management. |
|
V3881 | Elagolix sodium | 832720-36-2 | Elagolix sodium (NBI56418; ABT-620; Orilissa), the sodium salt of Elagolix, is an orally bioavailable and small molecule antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM) approved on 7/23/2018 by FDA for the management of moderate to severe pain associated with endometriosis. |
|
V75399 | Fsh receptor-binding inhibitor fragment(bi-10) | 163973-98-6 | FSH receptor-binding inhibitor fragment(bi-10) is a potent FSH antagonist. |
|
V51369 | GnRH antagonist 2 | 1709823-61-9 | GnRH antagonist 2 (formula I) is a GnRH receptor blocker (antagonist) that may be utilized in the research/study of endometriosis. |
|
V75396 | GnRH Associated Peptide (1-24), human (GAP (1-24), human) | 148943-65-1 | GnRH Associated Peptide (GAP) (1-24), human is the 1-24 fragment of human gonadotropin-releasing hormone-related peptide (GAP) (hGAP-1-24). |
|
V75403 | GnRH Associated Peptide (25-53), human (GAP (25-53), human) | 106061-19-2 | GnRH Associated Peptide (GAP) (25-53), human is the 25-53 fragment (hGAP-25-53) of human gonadotropin-releasing hormone-related peptide (GAP), which can be produced as an immunogen including MC-1, MC- 2 and MC-3. |
|
V75394 | GnRH Associated Peptide (GAP) (1-13), human | 100111-07-7 | GnRH Associated Peptide (GAP) (1-13), human is an amino acid (AA) peptide fragment derived from GnRH. |
|
V75388 | GnRH-R antagonist 1 | 2826273-90-7 | GnRH-R antagonist 1 (compound 21a) is a GnRH-R antagonist (inhibitor) with good oral safety and membrane permeability. |
|
V21736 | Goserelin Acetate | 145781-92-6 | Goserelin is a synthetic decapeptide analogue of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. |
|
V80510 | Kisspeptin-54(human) TFA (Metastin(human) TFA) | Kisspeptin-54(human) TFA (Metastin(human) TFA) is an endogenous ligand of kisspeptin receptor (KISS1, GPR54), binding to rat and human GPR54 receptors with high affinity, and its Kis are 1.81 respectively. | |
|
V75395 | Lamprey LH-RH I | 102634-23-1 | Lamprey LH-RH I, a gonadotropin-releasing hormone that increases plasma steroid levels and stimulates ovulation in lampreys, has no effect on other animal models. |
|
V75398 | LH-RH (4-10) | 51776-33-1 | LH-RH (4-10) is a heptapeptide and one of the main products of gonadotropin-releasing hormone (LHRH) degradation by the pituitary gland and hypothalamus. |
|
V75401 | LH-RH (7-10) | 38482-71-2 | LH-RH (7-10) is a tetrapeptide and one of the main degradation products of gonadotropin-releasing hormone (LHRH) degraded by the pituitary gland and hypothalamus. |
|
V75387 | Merigolix | 1454272-94-6 | Merigolix is a potent gonadotropin-releasing hormone GnRH antagonist. |
|
V75400 | Onvitrelin ucalontide (Phor18-LHRH (338613)) | 1174415-90-7 | Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analog of luteinizing hormone-releasing hormone (LHRH) with anti-tumor activity. |
|
V75383 | Phoenixin-14 (PNX-14) | 1415039-79-0 | Phoenixin-14 (PNX-14) is an endogenous active isoform that produces anxiolytic effects by activating the mouse AHA GnRH system. |
|
V4596 | Relugolix | 737789-87-6 | Relugolix (formerly TAK-385; TAK385; trade names: Orgovyx and Relumina) is a non-peptidyl and orally bioactive antagonist of gonadotropin-releasing hormone (GnRH) approved in 2020 for use in the treatment of prostate cancer in men and uterine fibroids in women. |
|
V76518 | sGnRH-A acetate | sGnRH-A acetate is a salmon gonadotropin-releasing hormone (GnRH) analogue. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
